TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69

August 14, 2015.  TWi Pharmaceuticals, Inc. today announced that its board had approved 2015 first half financial results; the cumulative 1st half sales revenues reached NT$157 million, with Q2'15 sales revenues reaching NT$83 million, posting a growth of 13% over Q1'15.  Q2'15 gross profit reached NT$21 million, resulting in a gross margin of 25%, which in dollar amount grew 73% over Q1'15.  After deducting operating expense and adding non-operating income, the pretax profit for 2Q 2015 was NT$64 million and after tax EPS was NT$0.69.  The 2Q results included a net non-operating income of NT$272 million.

The management explained that, after several years of hard work, the Company had launched generic products in its own label in the U.S. market in the first half of 2015, which contributed to the 25% gross margin for the 2Q'15.  The operating results in 2Q 2015 validated the strategy of successfully developing and commercializing high-barrier generic products for the U.S. market.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

Contact :
Eric Lin
Tel: +886-2-2657-3350 #407
email: eric.lin@twipharma.com